跳至主導覽 跳至搜尋 跳過主要內容

SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2

  • Young-Suk Lim
  • , Chun-Yen Lin
  • , Jeong Heo
  • , Ho Bae
  • , Wan-Long Chuang
  • , Tak Yin
  • , Owen Tsang
  • , Claire Fournier
  • , Aric Josun Hui
  • , Huy Trinh
  • , Carol Yee Kwan Chan
  • , Susanna K. Tan
  • , Yang Zhao
  • , John F. Flaherty
  • , Vithika Suri
  • , Anuj Gaggar
  • , Dianna M. Brainard
  • , Stephen Ryder
  • , Harry La Janssen

研究成果: 期刊稿件文章同行評審

原文美式英語
期刊Gut
70
DOIs
出版狀態已出版 - 2021

UN SDG

此研究成果有助於以下永續發展目標

  1. SDG3 健康與福祉
    SDG3 健康與福祉

引用此